Management of Incidentally Discovered Fatty Liver on Ultrasound

Terminology Update (2023 Onwards)

Step 1: Initial Assessment After Incidental USG Finding

History and Clinical Evaluation

• If the patient has symptoms or abnormal liver biochemistries - formally evaluate for MASLD
• If asymptomatic with normal LFTs - assess metabolic risk factors and exclude secondary causes

• Alcohol intake (>2 drinks/day in women, >3/day in men over 12 months suggests alcohol-related disease)
• Medications known to cause steatosis (amiodarone, tamoxifen, methotrexate, corticosteroids, valproate)
• Family history of metabolic disease
• Features of metabolic syndrome: obesity, T2DM, hypertension, dyslipidemia

Step 2: Exclude Secondary Causes of Hepatic Steatosis

• Harrison's 22E notes: an AST/ALT ratio >2 points toward alcohol-related disease
• AST/ALT >2:1 = alcohol; ALT rarely >150-200 IU/L in alcoholic disease

Step 3: Baseline Lab Workup

• LFTs: ALT, AST, GGT, ALP, bilirubin, albumin, PT/INR
  • Note: Normal ALT is 29-33 U/L (men), 19-25 U/L (women) - standard lab "normals" are too generous
• CBC, fasting glucose/HbA1c
• Fasting lipids (total cholesterol, LDL, HDL, triglycerides)
• Thyroid function (TSH)
• Serum ferritin + transferrin saturation (to exclude hemochromatosis)
• Viral hepatitis serologies (HBsAg, anti-HCV)
• ANA, ASMA if autoimmune hepatitis suspected
• Fasting insulin/HOMA-IR (to assess insulin resistance)
• Renal function, uric acid

Step 4: Risk Stratify for Advanced Fibrosis (Most Important Step)

Non-Invasive Fibrosis Assessment Tools

• FIB-4 score = (Age × AST) / (Platelet count × √ALT)
  • < 1.30 = low risk (NPV ~90%)

  • 2.67 = high risk; consider advanced workup

• NAFLD Fibrosis Score (NFS) - uses age, BMI, hyperglycemia, platelets, albumin, AST/ALT

• VCTE (FibroScan/Vibration-Controlled Transient Elastography) - measures liver stiffness
• MRE (MR Elastography) - gold standard among non-invasive tools, best for morbidly obese

• High-risk FIB-4 + indeterminate elastography
• Diagnosis remains unclear after full workup
• Before starting specific pharmacologic therapy for MASH
• Biopsy remains the gold standard for diagnosing MASH and grading fibrosis

Step 5: Management

5A. Lifestyle Modification (Cornerstone of Treatment)

• 3-5% weight loss - improves hepatic steatosis
• 7-10% weight loss - resolves MASH inflammation
• >10% weight loss - can achieve fibrosis regression

• Mediterranean diet is preferred (best evidence for cardiovascular and MASLD benefit, culturally adaptable)
• Avoid: saturated fats, refined carbohydrates, sugar-sweetened beverages, high-fructose corn syrup
• Coffee - at least 3 cups/day has epidemiologic evidence for reduced fibrosis risk and HCC
• Avoid alcohol even in small amounts

• Minimum: 150 min/week moderate-intensity aerobic exercise (5 sessions × 30 min)
• More intensive: 60 min/week high-intensity gives equivalent benefit
• Resistance + aerobic combination is ideal
• Exercise improves insulin sensitivity independent of weight loss
• Harrison's 22E (p. 2749): "Sustained weight loss improves peripheral insulin sensitivity, cytokine-mediated inflammatory response, both hepatic and nonhepatic tissue stress, and even alterations in gut microbiota that contribute to metabolic dysfunction."

5B. Management of Metabolic Comorbidities

5C. Pharmacologic Therapies

• Semaglutide (GLP-1 agonist) - AASLD updated guidance (2025-2026) now includes semaglutide as a first-line option for MASH, supported by ESSENCE trial data (PMID: 41201884)
• Resmetirom (Rezdiffra) - FDA-approved March 2024, thyroid hormone receptor-β agonist, specifically for MASH with moderate-to-advanced fibrosis
• Pioglitazone - for biopsy-proven NASH (especially with T2DM); improves histology
• Vitamin E (800 IU/day) - for biopsy-proven NASH in non-diabetic adults; caution regarding long-term safety
• Washington Manual: "Vitamin E and/or pioglitazone may be used but treatment should be given only in biopsy-proven NASH in patients without contraindications with ample discussion of risks and benefits."

• Methotrexate - can worsen hepatic fibrosis
• High-dose statins in decompensated cirrhosis

5D. Surgical Options

• Bariatric surgery - for eligible obese patients (BMI >35, or >30 with comorbidities); prospective studies show significant improvement/resolution of MASH after bariatric surgery
• Liver transplantation - for NASH/MASH-related end-stage liver disease (ESLD); NAFLD is now the second leading cause of liver transplant listing in the US

Step 6: Monitoring and Follow-Up

Prognosis

• Simple steatosis = generally benign; ~25% may progress to NASH over time
• Steatosis alone: long-term mortality risk is primarily cardiovascular disease, not liver failure
• NASH with fibrosis: significant risk of cirrhosis, HCC, liver failure
• ~1/3 of NASH patients develop progressive fibrosis over 5 years
• Older age, diabetes, and hepatocyte ballooning/fibrosis on biopsy are predictors of progression
• Goldman-Cecil Medicine: "The long-term complications in patients with simple steatosis generally result from cardiovascular disease and atherosclerosis, not from liver failure."

Key Recent Evidence Updates

• Resmetirom (2024) - first FDA-approved drug specifically for MASH with liver fibrosis
• Semaglutide (AASLD 2025-2026) - updated guidance supports use for MASH. AASLD Practice Guidance update (PMID: 41201884)
• MASLD nomenclature - adopted internationally 2023; includes a "cardiometabolic criterion" (at least one of: overweight/obesity, T2DM, hypertension, dyslipidemia, or metabolic syndrome)

Quick Summary Algorithm

Incidental fatty liver on USG
        ↓
Rule out secondary causes (alcohol, meds, viral hepatitis, metabolic disorders)
        ↓
Baseline labs: LFTs, CBC, glucose, HbA1c, lipids, TSH, ferritin, viral serology
        ↓
Calculate FIB-4 score
        ↓
FIB-4 < 1.30         FIB-4 1.30-2.67         FIB-4 > 2.67
Low risk             Indeterminate            High risk
    ↓                    ↓                       ↓
Lifestyle          FibroScan/MRE            FibroScan/MRE
counseling         Hepatology referral      Biopsy likely
    ↓                                          ↓
Reassess                              Hepatology + consider
annually                              pharmacotherapy